• The full list of recent recruitments and promotions at Roswell Park Cancer Institute (The Cancer Letter, May 27, 2016).
• The open letter, signed by 150 organizations, to the Senate HELP committee on medical innovations legislation (The Cancer Letter, April 29, 2016).
• Fitzpatrick Letters: FDA's letter on inspections of hospitals on adverse outcomes reporting, and Rep. Mike Fitzpatrick's (R-Pa.) letter to Vice President Joe Biden on medical device safety regulations, the Cancer Moonshot and the FDA Oncology Center of Excellence (The Cancer Letter, April 15, 2016).
• The FDA's order granting PneumoLiner Class II device classification (The Cancer Letter, April 8, 2016).
• Amy Reed's consent form for her power morcellation procedure at Brigham and Women's Hospital (The Cancer Letter, April 8, 2016).
• Court documents regarding suits against AVEO Pharmaceuticals (Slamming the Door, March 11, 2016).
• The Centers of Medicare and Medicaid Services' transmittal describing its experiment that would alter ASP payment based on ZIP code, and a letter from oncology groups opposing the experiment (The Cancer Letter, March 4, 2016).
• Fact sheet and other documents about Patrick Soon-Shiong's Cancer MoonShot 2020 Program (The Cancer Letter, Jan. 15, 2016).

 2015 - Volume 41

• Rep. Mike Fitzpatrick's letter to the FDA Office of Criminal Investigations, requesting an investigation on possible failures to report adverse outcomes resulting from power morcellators (The Cancer Letter, Dec. 18, 2015). 
• A letter from a 46-member review group to FDA disputing the agency's risk estimates and restrictions on power morcellation (The Cancer Letter, Dec. 18, 2015).
• Correspondence between FDA and Congress, and Robert Lamparter and J&J/Ethicon on the controversy over power morcellation (The Cancer Letter, Nov. 20, 2015).
• The letter sent to the House Energy and Commerce Committee advocating for CT colonography screening (The Cancer Letter, Nov. 13, 2015).
• Complaint and Judge Fahey's ruling against Brigham & Women's Hospital for security measures against Hooman Noorchashm and Amy Reed (The Cancer Letter, Nov. 6, 2015).
• Federal Judge Rudolph Contreras's ruling on 340B discounts for orphan drugs (The Cancer Letter, Oct. 16, 2015).
• The Congressional letter to the GAO calling for investigation of power morcellators (The Cancer Letter, Sept. 11, 2015).
• A summary of the DAHANCA-10 trial (The Cancer Letter, Sept. 4, 2015).
• Judge Mehta's opinion regarding Amgen's subpoena against The Cancer Letter's Editor and Publisher Paul Goldberg (The Cancer Letter, Sept. 4, 2015).
• UT System Chancellor Bill McRaven's two letters to MD Anderson President Ronald DePinho and the Faculty Senate (The Cancer Letter Special Report, Aug. 14, 2015).
• The MD Anderson Executive Committee of the Faculty Senate draft white paper, presented to the UT System June 14 (The Cancer Letter, July 13, 2015).
• The slides presented by NCI Acting Director Douglas Lowy in his first director's report to the joint meeting of the NCAB and BSA (The Cancer Letter, July 3, 2015).
• The letter sent to Amgen from attorneys representing The Cancer Letter (The Cancer Letter, June 5, 2015).
• The protocol for the Duke breast cancer trial that treated Joyce Shoffner, and her complaint against Duke (The Cancer Letter, May 22, 2015).
• The white paper produced by MED-C (The Cancer Letter, May 8, 2015).
• MD Anderson officials respond to questions from The Cancer Letter (April 17, 2015).
• MD Anderson's Compensation Change Proposal and Budget Advisory Committee presentation (The Cancer Letter, April 17, 2015).
• Letters from Rep. Michael Fitzpatrick and Sen. Robert Casey to FDA on medical device regulations (The Cancer Letter, April 10, 2015).
• AAUP's draft report from its investigation of tenure dispute cases at MD Anderson, and the cancer center's response (The Cancer Letter, March 18, 2015).
• A compilation of legal documents related to the suit filed against Duke University (The Cancer Letter, Jan. 23, 2015).
• Holly Dressman's email to Joseph Nevins on her efforts to verify the topotecan signature in ovarian cancer (The Cancer Letter, Jan. 16, 2015).
• Moffitt Cancer Center's response to questions from the IOM committee (The Cancer Letter, Jan. 16, 2015).
• NCI statistician Lisa McShane's commentary on the Moffitt Letter (The Cancer Letter, Jan. 16, 2015).
• An interview with Anil Potti (The Cancer Letter, Jan. 9, 2015).

2014 - Volume 40

• A May 2014 version of a patient consent form for a Brigham & Women's Hospital study to assess leakage when using containment bags with power morcellators (The Cancer Letter, Nov. 21, 2014).
• The statements and letters from Senators to FDA on power morcellation (The Cancer Letter, Nov. 21, 2014).
• The data tables of NCI and NIH funding for 17 institutions from 2003 to 2013 (The Cancer Letter, Oct. 31, 2014).
• The complaint and settlement agreement in the case filed against Charles Bennett (The Cancer Letter, Oct. 31, 2014).
• The complaint filed by Pharmaceutical Research and Manufacturers of America against HHS and HRSA (The Cancer Letter, Oct. 24, 2014).
• The review committee's report recommending the closing of the Indiana University Health Proton Therapy Center (The Cancer Letter, Oct. 17, 2014).
• The Pharmaceutical Research and Manufacturers of America's (PhRMA) lawsuit against the Department of Health & Human Services/Health Resources and Services Administration for its 340B "interpretive" rule on the Affordable Care Act orphan drug exclusion (The Cancer Letter, Oct. 10, 2014).
• The legal files regarding the DOJ prosecutions of those involved with the supply chain moving counterfeit Avastin into the United States (The Cancer Letter, Oct. 3, 2014).
• The April 2006 letter sent from William McGivney to Genentech CEO Art Levinson (The Cancer Letter, Oct. 3, 2014).
• The full confidential document detailing a plan for MD Anderson's nationwide expansion (The Cancer Letter, Sept. 26, 2014).
• The back-and-forth correspondence between MD Anderson and the American Association of University Professors (The Cancer Letter, Sept. 19, 2014).
• The letter from Sens. Chuck Schumer and Kirsten Gillibrand to FDA Commissioner Margaret Hamburg regarding power morcellation (The Cancer Letter, Aug. 27, 2014).
• The Appendix in Support and the answer to the second amended complaint in the case against Caris Life Sciences (The Cancer Letter, Aug. 8, 2014)
• AAGL spokesperson Jubilee Brown's presentation slides and remarks July 11 to the FDA Obstetrics and Gynecology Devices Panel on power morcellation (The Cancer Letter, July 25, 2014).
• MD Anderson Faculty Senate's recommendations to the DePinho administration, Boyd's July 10 letter to AAUP, and Powis's letters to the administration regarding Kapil Mehta (The Cancer Letter, July 18, 2014).
• PhRMA's complaint regarding 340B, Judge Contreras's ruling, and the DOJ's response (The Cancer Letter, June 13, 2014).
• Hope Cancer Institute $2.9 million settlement agreement and complaint in Medicare overbilling allegations (The Cancer Letter, June 6, 2014).
• Letters of support for Kapil Mehta's tenure renewal at MD Anderson (The Cancer Letter, May 30, 2014).
• Zhengxin Wang's denial of appeal and his complaint to the EEOC (The Cancer Letter, May 30, 2014).
• MD Anderson's policy for faculty appeals (The Cancer Letter, May 30, 2014).
• The MD Anderson 2012 and 2014 BIG Survey results, and 835 pages of comments by MD Anderson employees (The Cancer Letter, May 23, 2014).
• The AAUP's 1940 and 1958 statements on tenure and faculty dismissal, and its 2013 recommended regulations (The Cancer Letter, May 16, 2014).
• Douglas Boyd's supporting documents sent to AAUP, making the case for an investigation into MD Anderson's decision to deny tenure to two faculty members (The Cancer Letter, May 16, 2014).
• Peter Bach's presentation to the CMS advisory committee on LCA's certification process (The Cancer Letter, May 9, 2014).
• A recording of NCI's conference call with patient advocates regarding NCTN (The Cancer Letter, May 2, 2014).
• The MD Anderson Faculty Senate report on renewal of tenure and "the presidential veto" (The Cancer Letter, April 25, 2014).
• Kapil Mehta's timeline of events and related documents as he sought renewal of his tenure at MD Anderson (The Cancer Letter, April 25, 2014).
• Zhengxin Wang's timeline of events and related documents as he sought to renew his tenure at MD Anderson (The Cancer Letter, April 25, 2014).
• The letter sent to investigators March 6, detailing NCI's plans for phasing out CCOP and the transition to NCORP (The Cancer Letter, April 11, 2014).
• The May 13 and June 24, 1994 issues of The Cancer Letter, covering Bernard Fisher's removal from the NSABP (The Cancer Letter, April 4, 2014).
• The presentations made by David Heimbrook and Robert Wiltrout regarding the Frederick National Lab (The Cancer Letter, Feb. 28, 2014).
• The white paper produced by GOG regarding NCI CTEP supported gynecologic cancer research trials (The Cancer Letter, Feb. 21, 2014).
• The full confidential document detailing a plan for MD Anderson's nationwide expansion (The Cancer Letter, Feb. 7, 2014).
• The Cancer Letter's Conversation with Peter Boyle, president of IPRI (The Cancer Letter, Jan. 31, 2014).
• The Cancer Letter's Conversation with John Seffrin, retiring CEO of the American Cancer Society (The Cancer Letter, Jan. 24, 2014).
• The Cancer Letter's Conversation with Mark Roh, president of Orlando Health Center (The Cancer Letter, Jan. 10, 2014).

2013 Volume 39

• Marie Huber's alternative explanation of the Provenge trial results, and her agreement with the SEC (The Cancer Letter, Dec. 6, 2013).
• The letters sent by members of the House and Senate to NCI Director Harold Varmus, and his response (The Cancer Letter, Dec. 6, 2013).
• The Cancer Letter's conversation with Clifford Hudis, president of the American Society of Clinical Oncology (The Cancer Letter, Nov. 22, 2013).
• The slide presentation of Roy Herbst, of Yale Cancer Center, unveiling the master protocol (The Cancer Letter, Nov. 15, 2013).
• The Cancer Letter's conversation with Max Wicha, director of the University of Michigan Comprehensive Cancer Center (The Cancer Letter, Nov. 8. 2013).
• A collection of emails sent by BioMarin's CEO, Jean-Jacques Bienaimé, and Austin attorney Andrea Sloan (The Cancer Letter, Nov. 8. 2013).
• The CON Approvals for Sibley Memorial Hospital and MedStar Health (The Cancer Letter, Oct. 25, 2013).
• The data set used by Nevins and Potti in their study using genomic predictors (The Cancer Letter, Oct. 18, 2013).
• The lawsuit filed by Joyce Shoffner against Duke University, Joseph Nevins, Anil Potti, et al. (The Cancer Letter, Sept. 9, 2011).
• The Cancer Letter's Conversation with Erin Fox, director of the University of Utah's Drug Information Service (The Cancer Letter, Oct. 11, 2013).
• The Cancer Letter's Conversation with MSKCC's José Baselga (The Cancer Letter, Sept. 27, 2013).
• A new survey of MD Anderson's clinical faculty focused on patient safety (The Cancer Letter, Sept. 20, 2013).
• MD Anderson Cancer Center's year-to-date July 2013 internal financial documents (The Cancer Letter, Sept. 6, 2013).
• MD Anderson's Faculty Senate survey (The Cancer Letter, Sept. 6, 2013).
• The complaint filed against Northwestern University, the plea agreement made by Feyifunmi Sangoleye, and the settlement agreement made between Northwestern and the Department of Justice (The Cancer Letter, Aug. 9, 2013).
• The lawsuits filed by Myriad Genetics against Gene By Gene and Ambry Genetics, as well as Myriad's injunction against Ambry Genetics (The Cancer Letter, July 26, 2013).
• A presentation given to an MD Anderson working group detailing the problems caused by inaccurate data reporting (The Cancer Letter, July 19, 2013).
• NIH response to questions from Congress on public relations and education spending levels (The Cancer Letter, July 12, 2013).
• NCI web analytics compared to those of other organizations that provide cancer information (The Cancer Letter, July 12, 2013).
• The NCAB working group's cancer centers core grants presentation to the joint BSA NCAB meeting (The Cancer Letter, July 5, 2013).
• The charges filed against MD Anderson breast cancer researcher Ana Maria Gonzalez-Angulo (The Cancer Letter, June 14, 2013).
• A conversation with MD Anderson's Hagop Kantarjian (The Cancer Letter, May 31, 2013).
• Documents relating to the renovation of Lynda Chin's MD Anderson office suite (The Cancer Letter, May 24, 2013).
• The slides from NCI Director Harold Varmus's address delivered at the AACR annual meeting (The Cancer Letter, April 26, 2013).
• A conversation with City of Hope CEO Michael Friedman (The Cancer Letter, April 5, 2013).
• In Their Own Words: The Complete MD Anderson Faculty Survey Results (The Cancer Letter, March 29, 2013).
• The Cancer Letter's Conversation with COG Chair Peter Adamson (The Cancer Letter, March 15, 2013).
• The 2007 MITRE Corp. report on NCI's communications programs (The Cancer Letter, March 1, 2013).
• The subcommittee review of NCI's communications-related budgets presented to the NCI Executive Committee (The Cancer Letter, March 1, 2013).
• An interview with Donald Trump, president and CEO of Roswell Park Cancer Institute regarding sequestration (The Cancer Letter, Feb. 22, 2013).
• A collection of interal documents and emails surrounding the creation and design of the NCI Cancer Bulletin (The Cancer Letter, Feb. 1, 2013).
• The Cancer Letter's conversation with NBCC President Fran Visco (The Cancer Letter, Jan. 25, 2013).
• NBCC's response to the Nature editorial (The Cancer Letter, Jan. 25, 2013).
• MD Anderson's 2012 Faculty Morale Survey results (The Cancer Letter, Jan. 18, 2013).
• MD Anderson's 2010 Faculty Morale Survey results (The Cancer Letter, Jan. 18, 2013).
• A Salary Review by the MD Anderson Faculty Senate (The Cancer Letter, Jan. 18, 2013).
• A reanalysis of the Faculty Senate's Salary Review by the MD Anderson administration (The Cancer Letter, Jan. 18, 2013).
• MD Anderson's Financial Report & Clinical Activity Update - November 2012 (The Cancer Letter, Jan. 18, 2013).
• Highlights from MD Anderson's Clinical Chairs Meeting with talking points - December 2012 (The Cancer Letter, Jan. 18, 2013).
• MD Anderson President Ronald DePinho's Town Hall Meeting - January 2013 (The Cancer Letter, Jan. 18, 2013).
• A recorded interview with Carolinas Healthcare System's Derek Raghavan. (The Cancer Letter, Jan. 4, 2013).

• William Gimson's resignation letter, from the Cancer Prevention & Research Institute of Texas (The Cancer Letter, Dec. 14, 2012).
• Confirmation of an inquiry by the Texas Office of the Attorney General into CPRIT's funding of Peloton Therapeutics (The Cancer Letter, Dec. 14, 2012).
• The letter from CPRIT's founding legislators expressing concern to CPRIT's investigators (The Cancer Letter, Dec. 14, 2012).
• The letter from the Travis County District Attorney to Kristen Doyle, CPRIT's general counsel (The Cancer Letter, Dec. 14, 2012).
• CPRIT's announcement of the appointment of Margaret Kripke as chief scientific officer (The Cancer Letter, Dec. 14, 2012).
• An audio recording of Kripke's telephone conference with reporters (The Cancer Letter, Dec. 14, 2012).
• A letter from Richard Schilsky to his colleagues at the University of Chicago.
• The American Society of Clinical Oncology's press release announcing Richard Schilsky being named chief medical officer.
• University of Chicago's notice to faculty announcing Richard Schilsky being named chief medical officer of the American Society for Clinical Oncology.
• MD Anderson's August 2012 Financials (The Cancer Letter, Oct. 12, 2012). 
• A recording of MD Anderson President Ronald DePinho's State of the Institution speech (The Cancer Letter, Oct. 12, 2012). 
• The CPRIT Email Archive obtained by The Cancer Letter detailing the agency's reaction to MD Anderson's incubator proposal (The Cancer Letter, Sept. 28, 2012).
• UT System documents pertaining to the hiring of DePinho and Chin (The Cancer Letter, Sept. 21, 2012).
• MD Anderson Moon Shots Program Backgrounder (The Cancer Letter, Sept. 21, 2012).
• MSP: Breast and Ovarian Cancer Backgrounder (The Cancer Letter, Sept. 21, 2012).
• MSP: CLL Backgrounder (The Cancer Letter, Sept. 21, 2012).
• MSP: Melanoma Backgrounder (The Cancer Letter, Sept. 21, 2012).
• MSP: AML MDS Backgrounder (The Cancer Letter, Sept. 21, 2012).
• MSP: Lung Cancer Backgrounder (The Cancer Letter, Sept. 21, 2012).
• Robert DePinho's letter to Rep. Fred Upton (The Cancer Letter, Sept. 14, 2012).
• AAMC's letter to Sen. Sheldon Whitehouse  (The Cancer Letter, Sept. 14, 2012).
• AACR's letter to Sen. Sheldon Whitehouse  (The Cancer Letter, Sept. 14, 2012).
• PANCan's Letter to Reps. Anna Eshoo and Leonard Lance  (The Cancer Letter, Sept. 14, 2012).
• CLS's letter to Rep. Fred Upton  (The Cancer Letter, Sept. 14, 2012).
• Pancreatic Cancer Action Network's advocacy materials packet including fact sheets for policymakers (The Cancer Letter, Aug. 3, 2012).
• A document describing how N-CORP will be divided into levels 1, 2 and 3 (The Cancer Letter, July 13, 2012).
• The MD Anderson-CPRIT Compliance Review Report (The Cancer Letter, June 15, 2012).
• A transcript of MD Anderson President Ronald DePinho's appearance on CNBC (The Cancer Letter, June 1, 2012).
• The MD Anderson IACS six-and-a-half-page-long grant application (The Cancer Letter, May 25, 2012).
• The appendix to the IACS grant application, including budgets (The Cancer Letter, May 25, 2012).
• Ronald DePinho's remarks to the Board of Visitors in October 2011 (The Cancer Letter, May 25, 2012).
• The NCI Memo circulated before the cancer center directors' April 19 retreat (The Cancer Letter, May 11, 2012).
• An outline of the 2013 CCSG Guideline Changes (The Cancer Letter, May 11, 2012).
• A draft of the 2013 CCSG Guidelines (The Cancer Letter, May 11, 2012).
• A summary of the 2013 CCSG Guideline Changes (The Cancer Letter, May 11, 2012).
• Director Cullen's letter to NCI's Weiss (The Cancer Letter, May 11, 2012).
• The letter sent by 11 cancer center directors to Weiss (The Cancer Letter, May 11, 2012).
• The Opposition to Seal, sent by attorneys representing Amelia Weber (The Cancer Letter, April 20, 2012).
• Urorad Healthcare's FAQ sheet regarding developing IMRT centers (The Cancer Letter, April 13, 2012).
• TwinCrest Group's flyer to urology practices offering in-office pathology (The Cancer Letter, April 13, 2012).
• Part one of a collection of files containing Craig Thompson's Motion to Dismiss, filed as part of the Abramson lawsuit (The Cancer Letter, March 23, 2012).
• Part two of a collection of files containing Thompson's Motion to Dismiss (The Cancer Letter, March 23, 2012).
• Agios Pharmaceuticals' Motion to Dismiss, filed against Abramson lawsuit (The Cancer Letter, March 23, 2012).
• UPenn's complaint against former cancer center director, Craig Thompson (The Cancer Letter, March 9, 2012).
• Attachments to UPenn's complaint (The Cancer Letter, March 9, 2012).
• The Abramson Institute's complaint against former cancer center director, Craig Thompson (The Cancer Letter, March 9, 2012).
• The Susan G. Komen Foundation 2010 Affiliation Policies document (The Cancer Letter, Feb. 3, 2012).
• The Susan G. Komen Foundation 2010 Affiliation Agreement document (The Cancer Letter, Feb. 3, 2012).
• FDA's letter to the Division of Medical Oncology, Duke University Medical Center (The Cancer Letter, Jan. 27, 2012).
• Letter to CDER from the Duke University Medical Center (The Cancer Letter, Jan. 27, 2012).
• FDA Establishment Inspection Report, January 2011 (The Cancer Letter, Jan. 27, 2012).
• NVCI co-founder Heather Murren's declaration in bankruptcy court (The Cancer Letter, Jan. 20, 2012).
• Restructuring consultant George Pillari's declaration in NVCI's bankruptcy court (The Cancer Letter, Jan. 20, 2012).
• The Cancer Letter's interview with Robert Young, former NCCN chairman: Part 1 and Part 2 (The Cancer Letter, Jan. 13, 2012).
• The Cancer Letter's interview with Catherine Harvey, NCCN's first executive director: Part 1 and Part 2 (The Cancer Letter, Jan. 13, 2012).
• The March 15, 1996, and Jan. 24, 1997, issues of The Cancer Letter (The Cancer Letter, Jan. 13, 2012).

• Anil Potti's application and letters of recommendation to the South Carolina licensure board (The Cancer Letter, Dec. 9, 2011).
• Duke University's letter to the president of the North Carolina Medical Board (The Cancer Letter, Dec. 9, 2011).
• NC Medical Board Reprimands Former Duke Doctor Anil Potti. The text of the consent decree.  
• The email sent by Jerome Yates, former American Cancer Society VP for research, regarding the society's restructuring (The Cancer Letter, Nov. 18, 2011).
• The TREAT Act, a model bill proposing two new options for FDA approval (The Cancer Letter, Nov. 18, 2011).
• NCI CTEP's RFA Presentation to the Board of Scientific Advisors (The Cancer Letter, Nov. 11, 2011).
• Exhibit E: Spreadsheets showing the overfill of Aranesp compared to Procrit, in US & Westmoreland vs. Amgen (The Cancer Letter, Oct. 28, 2011).
• The whistle-blower lawsuit of US & Westmoreland vs. Amgen Inc. (The Cancer Letter, Oct. 28, 2011).
• The US Preventive Services Task Force Systematic Review Of Evidence Draft Paper, via Annals of Internal Medicine (The Cancer Letter, Oct. 7, 2011).
• The jointly filed lawsuit against Duke University, Duke University Health System, Potti, Nevins, et al. (The Cancer Letter, Sept. 9, 2011).
• The filed lawsuit of Joyce Shoffner vs. Duke University, et al. (The Cancer Letter, Sept. 9, 2011).
• Citizen Oncology Foundation's analysis of the drug shortage (The Cancer Letter, Sept. 9, 2011).
• FDA CDER's Post-Hearing Submission against Avastin's MBC Indication (The Cancer Letter, Aug. 12, 2011).
• Genentech's Post-Hearing Submission in favor of Avastin's MBC Indication (The Cancer Letter, Aug. 12, 2011).
• The letter to Varmus and Doroshow from advocates for the Children's Oncology Group (The Cancer Letter, July 8, 2011).
• The letter to Varmus and Doroshow from patients involved in the adult cancer cooperative groups (The Cancer Letter, July 8, 2011).
• Aug. 5, 2005 issue of The Cancer Letter (The Cancer Letter, July 1, 2011).
• Claudia Henschke's affadavit used in class action suits against Philip Morris USA (The Cancer Letter, June 24, 2011).
• The 2009 tax filing by Henschke's Early Diagnosis and Treatment Research Foundation, Inc (The Cancer Letter, June 24, 2011).
• The caBIG Program Update presented to the Board of Scientific Advisors (The Cancer Letter, June 24, 2011).
• The First CALGB Protocol (The Cancer Letter, June 17, 2011).
• The GAO's Decision to deny Velos' request for reconsideration (The Cancer Letter, June 17, 2011).
• FDA CDER's Summary of Arguments supporting withdrawal of Avastin's breast cancer indication (The Cancer Letter Special Issue, May 27, 2011).
• Genentech's Pre-Hearing Summary of Evidence in support of maintaining Avastin's accelerated approval (The Cancer Letter Special Issue, May 27, 2011).
• The 2009 tax filing by Henschke's Early Diagnosis and Treatment Research Foundation, Inc (The Cancer Letter, April 29, 2011). 
• The 2009 tax filing by Henschke's Foundation for Lung Cancer: Early Detection, Prevention & Treatment (The Cancer Letter, April 29, 2011). 
• Velos protests NCI's decision to award a contract related to caBIG to Medidata (The Cancer Letter, April 22, 2011).
• The FDA's Avastin Decision Memorandum (The Cancer Letter, April 15, 2011).
• The CMS Provenge Decision Memo (The Cancer Letter, April 1, 2011).
• The Duke University official account of the history of the scandal (The Cancer Letter, April 1, 2011).
• The press release announcing the merger of ACOSOG, CALGB and NCCTG.
• BSA caBIG Assessment (The Cancer Letter, March 4, 2011).
• Response to CL Questions (The Cancer Letter, March 4, 2011).
• UPDATED Response to CL Questions (The Cancer Letter, March 4, 2011).
• Jeremy Berg - SMRB Comments (The Cancer Letter, Feb. 25, 2011).
• Velos GAO Decision 11-28-2008 (The Cancer Letter, Feb. 25, 2011).
• Velos GAO Decision 12-14-2009 (The Cancer Letter, Feb. 25, 2011).
• Velos Letter to Varmus (The Cancer Letter, Feb. 25, 2011).
• Original Award Doc to Velos from DOI (The Cancer Letter, Feb. 25, 2011).
• NCI Medidata Award Notification (The Cancer Letter, Feb. 25, 2011).
• Notice of Cancellation 12-15-10 (The Cancer Letter, Feb. 25, 2011).
• NCI - Velos Selected for Award Powerpoint (The Cancer Letter, Feb. 25, 2011).
• The letters from HHS to Congress regarding NCATS and NCRR (The Cancer Letter, Feb. 11, 2011).
• A transcript of the NIH town hall conference call with NCRR stakeholders (The Cancer Letter, Feb. 11, 2011).
• A transcript of the NIH town hall conference call with CTSA principal investigators (The Cancer Letter, Feb. 11, 2011).
• The SMRB final report of their Dec. 7 meeting, voting to approve the plan for NCATS (The Cancer Letter, Feb. 11, 2011).
• GOG White Paper argues for keeping the group separate (The Cancer Letter, Feb. 4, 2011). 
• Duke pre-IDE filing on Lung Metagene Score (The Cancer Letter, Jan. 28, 2011).
• FDA response to Duke pre-IDE filing (The Cancer Letter, Jan. 28, 2011).
• Internal Duke document listing trials and their regulatory status (The Cancer Letter, Jan. 28, 2011).
• Lisa McShane Testimony before IOM (The Cancer Letter, Jan. 28, 2011).
• Robert Becker Testimony before IOM (The Cancer Letter, Jan. 28, 2011).
• New Timeline of the Duke Scandal; Lung Metagene Score data (The Cancer Letter, Jan. 14, 2011).
• Internal NCI documents (zip files 1, 2 and 3) related to the Duke genomics controversy (The Cancer Letter, Jan. 7, 2011).